NCT02314169 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 39
- group Id
- BG001
- value
- 53
- group Id
- BG002
- value
- 51
- group Id
- BG003
- value
- 143
- units
- Participants
- groups
- description
- Patients receive nivolumab IV over 60 minutes once every two weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study. Biospecimen Collection: Undergo blood sample collection Computed Tomography: Undergo CT scan Magnetic Resonance Imaging: Undergo MRI Nivolumab: Given IV
- id
- BG000
- title
- Part A (Nivolumab)
- description
- Patients receive nivolumab once every 8 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study. Biospecimen Collection: Undergo blood sample collection Computed Tomography: Undergo CT scan Ipilimumab: Given IV Magnetic Resonance Imaging: Undergo MRI Nivolumab: Given IV
- id
- BG001
- title
- Part B1 (Nivolumab)
- description
- Patients receive nivolumab +/- ipilimumab once every 8 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study. Biospecimen Collection: Undergo blood sample collection Computed Tomography: Undergo CT scan Ipilimumab: Given IV Magnetic Resonance Imaging: Undergo MRI Nivolumab: Given IV
- id
- BG002
- title
- Part B2 (Nivolumab + Ipilimumab)
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 31
- upper Limit
- 71
- value
- 56
- group Id
- BG001
- lower Limit
- 45
- upper Limit
- 81
- value
- 59
- group Id
- BG002
- lower Limit
- 36
- upper Limit
- 77
- value
- 60
- group Id
- BG003
- lower Limit
- 31
- upper Limit
- 81
- value
- 59
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 42
- group Id
- BG002
- value
- 39
- group Id
- BG003
- value
- 109
- title
- Female
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 34
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 53
- group Id
- BG002
- value
- 47
- group Id
- BG003
- value
- 137
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 4
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 4
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 7
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 34
- group Id
- BG001
- value
- 50
- group Id
- BG002
- value
- 47
- group Id
- BG003
- value
- 131
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 39
- group Id
- BG001
- value
- 53
- group Id
- BG002
- value
- 51
- group Id
- BG003
- value
- 143
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- population Description
- The patients included in this baseline analysis were all patients who consented to the study.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 39
- group Id
- BG001
- value
- 53
- group Id
- BG002
- value
- 51
- group Id
- BG003
- value
- 143
- units
- Participants
- groups
- description
- Patients receive nivolumab IV over 60 minutes once every two weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study. Biospecimen Collection: Undergo blood sample collection Computed Tomography: Undergo CT scan Magnetic Resonance Imaging: Undergo MRI Nivolumab: Given IV
- id
- BG000
- title
- Part A (Nivolumab)
- description
- Patients receive nivolumab once every 8 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study. Biospecimen Collection: Undergo blood sample collection Computed Tomography: Undergo CT scan Ipilimumab: Given IV Magnetic Resonance Imaging: Undergo MRI Nivolumab: Given IV
- id
- BG001
- title
- Part B1 (Nivolumab)
- description
- Patients receive nivolumab +/- ipilimumab once every 8 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study. Biospecimen Collection: Undergo blood sample collection Computed Tomography: Undergo CT scan Ipilimumab: Given IV Magnetic Resonance Imaging: Undergo MRI Nivolumab: Given IV
- id
- BG002
- title
- Part B2 (Nivolumab + Ipilimumab)
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 31
- upper Limit
- 71
- value
- 56
- group Id
- BG001
- lower Limit
- 45
- upper Limit
- 81
- value
- 59
- group Id
- BG002
- lower Limit
- 36
- upper Limit
- 77
- value
- 60
- group Id
- BG003
- lower Limit
- 31
- upper Limit
- 81
- value
- 59
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 42
- group Id
- BG002
- value
- 39
- group Id
- BG003
- value
- 109
- title
- Female
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 34
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 53
- group Id
- BG002
- value
- 47
- group Id
- BG003
- value
- 137
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 4
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 4
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 7
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 34
- group Id
- BG001
- value
- 50
- group Id
- BG002
- value
- 47
- group Id
- BG003
- value
- 131
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 39
- group Id
- BG001
- value
- 53
- group Id
- BG002
- value
- 51
- group Id
- BG003
- value
- 143
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- population Description
- The patients included in this baseline analysis were all patients who consented to the study.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle